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Objectives: To evaluate the feasibility of 4-dimensional perfusion computed tomography
(CT) as an imaging biomarker for patients with hepatocellular carcinoma and metastatic liver
disease.
Methods and materials: Patients underwent volumetric dynamic contrast-enhanced CT on a 320-
slice scanner before and during stereotactic body radiation therapy and sorafenib, and at 1 and 3
months after treatment. Quiet free breathing was used in the CT acquisition and multiple techniques
(rigid or deformable registration as well as outlier removal) were applied to account for residual liver
motion. Kinetic modeling was performed on a voxel-by-voxel basis in the gross tumor volume and
normal liver resulting in 3-dimensional parameter maps of blood perfusion, capillary permeability,
blood volume, and mean transit time. Perfusion characteristics in the tumor and adjacent liver were
correlatedwith radiation dose distributions to evaluate dose-response. Paired t tests assessed change in
spatial and histogram parameters from baseline to different time points during and after treatment.
Technique reproducibility as well as the impact of arterial and portal vein input functions was also
investigated using intra- and inter-subject variance and Bland-Altman analysis.
Results: Quantitative perfusion parameters were reproducible (5.7%; range, 2%-10%)
depending on tumor/normal liver type and kinetic parameter. Statistically signiﬁcant reductions
in tumor perfusion were measurable over the course of treatment and as early as 1 week after
sorafenib administration (P < .05). Marked liver parenchyma perfusion reduction was seen
with a strong dose-response effect (R2 Z 0.95) that increased signiﬁcantly over the course
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poral changes in liver tumor perfusion and normal liver function following antiangiogenic
therapy and radiation treatment warranting further evaluation of biomarker prognostication.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society
for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Quantitative functional imaging methods have become
more prominent in the management of solid tumors for
staging of disease, target deﬁnition, and early response
detection of treatment efﬁcacy.1,2 Moreover, measuring
vascular change is important when optimizing the timing
of antiangiogenic therapies and radiation therapy.3
Dynamic contrast-enhanced (DCE) computed tomogra-
phy (CT) of the liver, with high resolution and clinical
convenience, is a key potential method in this regard.2
Advances in perfusion imaging analysis techniques and
scanner acquisition capabilities have brought voxel-based
perfusion imaging of the liver into the realm of possibil-
ities and it is now well-understood that the absence of
3-dimensional (3D) volumetric representation results in
poor accuracy and robustness as well as a lack of het-
erogeneity information, which is much-needed to address
and understand changes in tumor behavior and treatment
response.4-6
Traditionally, motion artifacts resulting from patient
movement during image acquisition have further
confounded parametric perfusion maps because DCE-CT
acquisitions can potentially run up to 4 minutes to do
permeability studies.7 This can create signiﬁcant problems
for CT perfusion, particularly for those organs subject to
respiratory motion, such as the lung or liver. Careful
instruction to the patient helps to minimize this,7 but also
reduces scan frequency and requires substantial patient
cooperation to ensure reproducibility which is not always
possible. Respiratory-induced organmovement is largest in
the superior-inferior direction8,9; therefore, making it
almost impossible to compensate for with limited-slice
imaging.
Multislice CT technology now provides the possibility
of performing fast acquisitions of wide volumetric scans
using 256- or 320-slice detectors.10 This technology
offers great advantages over conventional CT perfusion
imaging studies and brings the ﬁeld-of-view (FOV) to
levels similar to DCE-magnetic resonance imaging (MRI)
scans allowing for true dynamic volume acquisitions
without the need to move the couch or detector such that
every volume represents a particular respiration phase and
intrascan image registration becomes an option. The main
goal of the work presented here was to: (1) assess the
feasibility of using volumetric CT perfusion to provide3D perfusion parameter maps in a challenging group of
patients with hepatocellular carcinoma (HCC) and liver
metastases subject to breathing motion and (2) assess its
sensitivity and robustness in capturing changes in liver
and tumor perfusion as a response to treatment for use as a
noninvasive imaging biomarker. Having the ability to
measure permeability and perfusion would be beneﬁcial,
especially in this patient group, because these physio-
logical changes can happen long before there is any
evidence of tumor volume change seen on conventional
imaging and could aid in the early selection of the most
appropriate treatment regime.Methods and materials
Patients and treatment
Patients with liver cancer, being treated as part of a
research ethics board (REB)-approved study of liver
stereotactic body radiation therapy (SBRT) and
sorafenib,11 underwent volumetric DCE-CT under a
further elective REB-approved companion imaging study.
Three patients had HCC and 1 had multiple liver metas-
tases, resulting in a total of 6 tumors considered in this
study. One tumor had a necrotic core. All patients were
surgically unresectable and treated with SBRT and
sorafenib with sorafenib doses ranging from 200 to 400
mg by mouth twice daily and SBRT doses ranging be-
tween 30 and 54 Gy given in 6 fractions over 2 weeks, on
a phase 1 study.11
Volumetric liver DCE-CT on a 320-slice CT
Patients had volumetric CT perfusion scans within 2
weeks before RT or sorafenib (baseline), 1 week after the
start of sorafenib (pre-RT), in the middle of RT, and 1 and
3 months after treatment. Each scan was acquired under
quiet free breathing as a dynamic volume time sequence
on a 320-slice CT scanner (Toshiba, Aquilion One)12 after
intravenous injection of iodixanol (Visipaque320, GE
Healthcare) at 2 mL/kg (to a maximum of 150 mL) at 4
mL/second with the aim of assessing tumor permeability
as well as perfusion. The scan parameters (100 mAs, 120
kV, 0.5-second gantry rotation) were optimized to balance
image quality with CT dose and tube heating, resulting in
Figure 1 A graphical depiction of the outlier removal method. (Top) The “distortion score” of each volume of the DCE-CT scan is
calculated and the points above 1.3 standard deviations from the mean are marked for removal. (Bottom) The dropped points correlate
with peaks in the breathing trace. AU, arbitrary unit; Ktrans, kinetic parameters of perfusion.
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volumes were acquired every 1.5 seconds (until 57 sec-
onds) for fast sampling of the uptake curve and peak
enhancement; then at 2.5-second intervals between 65 and
96 seconds; and consequently every 10 seconds until 255
seconds to sample slower changing contrast decrease and
allow for permeability modeling. Nominal scan times for
assessment of liver vascularity only typically run between
60 and 120 seconds.13 The resulting volumetric CT dose
index (CTDIvol) was 60 cGy. This resulted in 60 volumes
of 160 slices reconstructed at (0.46  0.46  1mm) voxel
size and 512  512  320 FOV matrix, allowing
coverage of almost the entire liver (or near entire) at each
time point (baseline range, 978-1682 mL).
The arterial perfusion and portal venous perfusion CT
volumes from the dynamic time sequence were chosen at
20 and 60 seconds, respectively, after the CT signal in the
aorta enhanced by 100 Hounsﬁeld units. Arterialperfusion, portal venous perfusion, and parenchyma
perfusion volume scans were registered to the arterial
perfusion scan from the original planning triphasic data
with the intention of correlating perfusion changes with
the dose distributions, and assessing whether the perfu-
sion scan could replace the triphasic planning scan for
future routine practice. This would further minimize the
overall CT scan dose for the patient.Motion correction and image registration
A ﬁnite-element biomechanical motion model was
implemented to allow for deformable image registration
between all volumes of the volumetric DCE-CT time
series.14 This model was then adapted for each volume
using navigator channels, which are rectangular boxes to
capture edge detection. These were placed on the dome of
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shift of the liver in each volume that consequently
determined the adaptation level of the motion model to
each volume.
However, except for patient 1, even the large 16-cm
scan coverage was not always sufﬁcient to have the
entire liver visible in every single phase of the DCE-CT
time sequence under free breathing conditions to allow
the creation of a motion model. Therefore, the use of an
automated distortion factor was implemented to
quickly evaluate the level of motion distortion by ﬁrst
classifying each voxel of the scan into air, tissue, or
bone based on their average precontrast CT number.
For each DCE volume, the number of voxels that
changed classiﬁcation from 1 time point to the next was
totaled and deﬁned a distortion score (arbitrary unit).
Voxels classiﬁed as tissue that changed to bone were
not counted as they could represent contrast voxels.
Volumes, which had a score higher than 1.3  the
standard deviations from the mean score were dropped
from the functional analysis data set. This is method is
being referred to as the “outlier” approach and the
cutoff threshold of 1.3 sigma was determined experi-
mentally based on balancing reducing the extent of
motion, as represented by the distortion score, with
DCE temporal sampling requirements. As can be seen
in Fig 1, the distortion score is synchronized with the
navigator channel motion patterns. A comparison be-
tween the outlier method, a 1-dimensional rigid regis-
tration along the superoinferior direction and a full
deformable registration correction was performed on
the baseline scan for patient 1 where the breathing
extents were available to generate a motion model for
the patient. The resulting pharmacokinetic parameter
histograms were compared between the 2 techniques.4D kinetic modeling for volumetric perfusion CT
analysis
Kinetic analysis was done on every voxel of the liver,
tumor included, using an in-house 4-dimensional (4D)
temporal dynamic analysis method, which enables auto-
mated parametric analysis based on patient-speciﬁc
dynamic behavior of contrast ﬂow.15 This has been vali-
dated using a dynamic ﬂow phantom capable of creating
typical liver enhancement curves5,16 and shown to
improve sensitivity of perfusion CT as an imaging
biomarker in a recent study of brain metastases treated
with stereotactic radiosurgery.4 The modiﬁed Tofts
model17 was used to estimate kinetic parameters of
perfusion (Ktrans [mL/g/min]), extracellular volume
(ve [mL/g]), and the whole blood volume per unit of tissue
(Vb [mL/g]) because most tumors were HCC
18 and rely
on arterial single input ﬂow. Semiquantitative measures of
perfusion such as the maximum slope of the uptake curve,maximum contrast intensity, the time-to-maximum
intensity, the mean transit time, and the area under the
curve (AUC) were also evaluated. The arterial input
function (AIF) was chosen in the aorta at the level of the
diaphragm because it was the most reproducible and
stable measurement of ﬂow.
Reproducibility of perfusion parameters
A repeat baseline DCE-CT scan was conducted in 1
patient (patient 4) 1 day later, to assess perfusion
parameter reproducibility. Gross tumor volume (GTV)
kinetic parameters as well as unirradiated liver and spleen
parenchyma regions of interest (ROIs) were compared on
both baseline scans. Bland-Altman analysis was used to
determine the reproducibility for direct voxel-to-voxel
comparison as well as pooled variation and correlation
between the median and skew parameters of the 3D
histograms. Although not recommended for routine use,
this double baseline was REB-approved for establishing
feasibility.
Tumor perfusion changes over time
Voxel-based perfusion parameters were obtained
within every GTV and moment analysis was done on the
histograms of both AUC and Ktrans results (ie, calculating
the mean, median, standard deviation, skewness, and
kurtosis of the distribution in the ROI, with the latter 2
describing the heterogeneity within the tumor). A linear
regression was done of the moment analysis results over
the course of treatment.
Quantiﬁcation of liver parenchyma perfusion
following treatment
The liver minus GTV was deﬁned as liver parenchyma
and the ﬁrst exhale volume of the DCE-CT scan before
contrast arriving was registered to the planning CT scan
using ROI-based mutual information. This volume was
found by retrospectively observing the liver motion in a
reconstructed time sequence and selecting the volume
with the highest diaphragm position. The planning CT
was also obtained in exhale, using automated breathing
control19 or voluntary exhale breath hold (for patients
treated with abdominal compression). The treatment
isodose lines were converted into contours in 5-Gy
increments between 0.5 and 55 Gy and perfusion
parameters correlated to the corresponding dose level.
Consequently, a linear regression was done of the changes
in perfusion parameters Ktrans and AUC at different time
points throughout treatment. The strength of this corre-
lation was compared with the received “normal” paren-
chyma dose.
Figure 2 The effect of outlier removal, 1-dimensional rigid registration, and deformable registration on Ktrans histograms. 1D, 1-
dimensional; 3D, 3-dimensional; Ktrans, kinetic parameters of perfusion.
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Image registration during DCE-CT acquisition
Deformable image registration was compared with the
outlier method for the baseline scan of patient 1 and the
resulting Ktrans histogram of the tumor is displayed in
Fig 2 for every method.
The 1-dimensional rigid and outlier removal methods
both resulted in almost identical mean values and only
slight variations in histogram shape. There was a subtle
increase in the number of lower Ktrans values for the
deformable registration (as seen in the higher skewness and
kurtosis values for the histogram), suggesting more of the
necrotic region of the tumor was being included in the GTV
for this patient. There will be limited uptake of contrast
agent in the necrotic voxels because of low blood ﬂow rates
and higher interstitial ﬂuid pressure,20 resulting in a larger
number of low Ktrans values in the 3D histogram. For 3 of
the 4 patients over the course of treatment (n Z 16) the
cutoff threshold consistently removed 8 of 69 data points
(11.7%) with a standard deviation of 1.6 points (2.0%) for a
coefﬁcient of variation of 20.2%. The fourth patient was
scanned with arms down, which greatly increased artifacts
in the DCE-CT images; however, the algorithm stillremoved a consistent, if slightly higher, number of frames
across all time points 15 of 69 (21.7%) with a standard
deviation of 2 frames (2.8%), coefﬁcient of variation
13.3%. In all cases, the method removed enough points to
reduce the overall amount of motion while maintaining on
average 87% of the frames to keep sufﬁcient temporal in-
formation. Based on these results, it was determined that the
outlier removal was effective at removing themore extreme
breathing points, especially on the inhale phase, and that the
rigid registration did not change the histograms in any
meaningful way. From this point on, only outlier removal
was applied within the analysis because it could be auto-
mated and is computationally inexpensive.
AIF: Individual sensitivity
Figure 3 shows the AIFs measured in the aorta at the
level of the diaphragm at every time point for all patients.
The difference in AIF peak shapes for patient 4 can be
explained by the fact there was an unplanned pressure
shutoff at intravenous injection during one of the pre-RT
scan as well as at 1-month follow-up, hence partially
contributing to the baseline variability. Contrast injection
was not adjusted after the unplanned shutoff to allow for
comparison between DCE scans. The unaffected baseline
Figure 3 Arterial input function as measured in the aorta for different imaging days throughout treatment (Tx) for all 4 patients. CT,
computed tomography; HU, Hounsﬁeld units; PT, patient; RT, radiation therapy.
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gradual increase in the peak enhancement from baseline
to progressively later imaging time points reaching a
maximum difference of 20% for all patients except for the
3-month follow-up on patient 3, indicating a higher blood
pressure as treatment continued (see Discussion),
although the small number of cases did not allow for full
signiﬁcance (P < .05) to be reached. For the latter scan,
the patient’s arms were down, causing a lot of streaking
artifacts in the DCE-CT scan.
Reproducibility of perfusion parameters
A repeat baseline DCE-CT scan was conducted in
patient 4 and median perfusion values within each of the 3
GTVs aswell as a control ROI in the liver parenchymawere
compared as shown in Table 1. The percentage Ktrans error
ranged between 2% and 10% in the tumor ROIs (Pearson
RZ 0.93) and was 4% in the control ROI in unirradiated
liver parenchyma (Pearson R Z 0.86). Direct voxel-to-
voxel correlation is more prone to errors in ROI registra-
tion; nevertheless, Bland-Altman analysis of Ktrans values
resulted in high coefﬁcients of repeatability of (0.878,
0783, and 0.5) in tumor lesions A, B, and C, respectively,
and 0.6 in the liver control ROI. The standard deviation in
ve and AUC was sometimes larger because they are more
prone to the kinetic modeling ﬁt and AIF shape.
Tumor vascular permeability and perfusion
changes over time
Using the automated temporal dynamic analysis
approach, it was possible to create 3D parameter maps
and histograms describing the tumor vascular physiologyand its heterogeneity. An illustration of changes in
perfusion Ktrans, permeability/interstitial space ve, and
AUC values over the course of treatment are shown in
Fig 4 for patient 1 with HCC.
The pre-RT DCE-CT scan showed a decrease in tumor
perfusion after administration of sorafenib compared with
baseline as well as an increase in skewness and kurtosis of
the perfusion histogram distribution in each tumor (Fig 5).
Although statistically insigniﬁcant in this small group
(Ktrans  14.8%  31.8%, P > .5), the trend was seen in
all but 1 of the tumors that had a necrotic core.
During RT, tumor perfusion increased again and to
levels higher than baseline perfusion in all but 1 case
(patient 1, HCC) (Ktrans þ 16%  7.1%, P Z .013),
whereas permeability remained lower than baseline
during RT for those same 5 tumors (ve  27.8  15%,
P Z .021). Following RT, a signiﬁcant decrease in
perfusion was seen at 1 month relative to baseline in
all but the same outlier (patient 1) (Ktrans  48.1% 
37%, P Z .038; ve  38.9  37.0, P Z .087). At 3
months following RT, Ktrans had decreased even further
(Ktrans  32.8  23.2, P Z .0262) but no permeability
changes were noticeable.
Normal liver perfusion response to dose and
sorafenib
The effects of radiation dose and sorafenib on normal
liver parenchyma are illustrated in Fig 6 with an overall
decrease in perfusion (Fig 6A) seen over the course of
treatment for most cases. AUC measurements show little
trending (Fig 6B). Measurements pre-RT, but after sor-
afenib administration, can detect some changes depending
on the distance to the tumor (reduction in three-fourths of
Table 1 Variation in kinetic parameters as calculated from 2 baseline DCE-CT scans
Double baseline DCE-CT (patient 4)
ROI Ktrans (L/min) Ktrans (% error) ve (L/min) ve (% error) AUC (HU/s) AUC (% error)
Tumor 4A 0.310  0.032 10.23 0.26  0.03 12.03 14,777  1491 10.09
Tumor 4B 0.509  0.012 2.45 0.26  0.01 5.21 15,472  2995 19.36
Tumor 4C 0.329  0.020 6.09 0.22  0.05 21.72 12,498  465 3.72
Liver control 0.309  0.013 4.12 0.22  0.02 9.92 12,425  1544 12.43
Mean 5.72 11.40 12.22
AUC, area under the curve; DCE-CT, dynamic contrast-enhance computed tomography; HU, Hounsﬁeld units; Ktrans, kinetic parameters of perfusion;
ve, extracellular volume.
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statistically signiﬁcant (P < .005). The correlations be-
tween dose received and reduction in Ktrans values at later
time points are similarly statistically signiﬁcant (P < .05)
with correlation coefﬁcients R2 between dose and Ktrans
reduction beginning at 0.331 for pre-RT and becoming
as strong as 0.95 at 3 months.Discussion
In this initial exploratory study, it was investigated
whether 4D DCE-CT of the liver was feasible under free
breathing conditions and could detect spatial and temporal
changes in both tumor and liver parenchyma perfusion
and permeability in response to treatment. It was possibleFigure 4 Kinetic modeling results for patient 1 over the course of tr
(Top) Perfusion from the vasculature into the interstitial space (Ktrans
extracellular space ve. (Bottom) Median area under the curve (AUC)
RT, radiation therapy.to generate voxel-based kinetic parameter maps in all
patients using a temporal dynamic perfusion analysis
method. In all but 1 case, a decrease in tumor perfusion
was seen 1 week after administration of sorafenib but
before RT, compared with baseline (P Z .035, n Z 5).
This supports the hypothesis that sorafenib “normalized”
the tumor vascularization, leading to decrease in intersti-
tial tumor pressure and improving tumor perfusion.
Coincidentally, the outlier corresponded to a case in
which the intravenous injection suffered from a pressure
shutoff. These results are in line with Cyran et al (2011),21
who investigated the use of DCE-MRI for monitoring the
effects of sorafenib on experimental prostate carcinoma
with immunohistochemical validation. An interesting fact
is that a higher peak AIF was measured postdrug/pre-RT
by approximately 20%. Although this was not statisticallyeatment showing histograms of kinetic parameters in the tumor.
). (Middle) Permeability-fractional volume of the extravascular-
of signal enhancement. Ktrans, kinetic parameters of perfusion;
Figure 5 Ktrans histograms for all 4 patients (6 tumors) over the course of treatment. The double baseline in patient 4 is overlaid in red.
GTV, gross tumor volume; Ktrans, kinetic parameters of perfusion; PT, patient; RT, radiation therapy.
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be hypothesized that this is correlated with sorafenib-
induced hypertension as was previously reported.22
Future studies with DCE-CT might replace a triphasic
scan but only if the mAs at the respective arterial perfu-
sion and parenchyma perfusion time points are increasedFigure 6 Effects of treatment on liver parenchyma perfusion (patie
together with isodose lines over time. (B) Changes in median perfusi
Changes in AUC from signal enhancement over time and in functio
patient; RT, radiation therapy.above the low-dose DCE scanning settings and the full
liver can be captured in the FOV.
During RT, tumor perfusion values increase again as
can be understood from the fact that radiation damage
results in cell apoptosis and an increase in extracellular
space.23 This is supported by an increase in interstitialnt 1). (A) Illustration of dose distribution overlaid on CT image
on value Ktrans over time and in function of received dose. (C)
n of received dose. Ktrans, kinetic parameters of perfusion; PT,
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decline for 5/6 cases. Histogram comparison over time for
the outlier case suggests some level of renormalization at
postdrug scan time with a high number of low-perfusion
voxels that even out over the course of treatment, corre-
sponding with the presence of the necrotic core. In these
situations, it might be argued there is less need for
biomarker analysis before standard Response Evaluation
Criteria in Solid Tumors24 change in tumors.
Double baseline DCE-CT scans indicated an average
reproducibility of 5%, which is an order of magnitude
better than perfusion variability reported previously using
DCE scans 1 week apart on a 16-slice CT scanner,25 as
well as from DCE-MRI measurements.26 This is likely
also a conservative estimate given the unplanned pressure
shutoff of 1 of the scans.
A limited number of publications has discussed
perfusion CT for assessment of normal liver changes
following radiation27 and to the best of our knowledge no
reports exist on the use of volumetric DCE-CT for tumor
response evaluation and biomarker assessment for HCC
and liver metastases. Figure 5 illustrates a strong dose-
response effect on normal liver perfusion. Although the
dose-response mechanism is compounded by the effect of
sorafenib, the decrease in perfusion with increasing dose
can be seen at 1 and 3 month following treatment by an
approximate 1% reduction per Gy received (R2 Z 0.9,
P < .004). This is similar to values reported by Cao et al
(2008) using a 16-slice CT scanner and breath hold DCE-
CT acquisition, who estimated a 1.2% reduction in
venous perfusion per Gray. Careful deﬁnition of tumor
volume and normal liver is clearly important as the voxels
in the high-dose regions (50 Gyþ) close to the tumor
show an increase in perfusion that is likely from invisible
tumor microscopic disease or underlying cirrhosis.
Although not the focus of this work, describing the
background liver as “normal” is something that needs to
be veriﬁed in patients with liver malignancies, because
many patients have underlying cirrhosis. In this study, all
patients had Child-Pugh A scores and were treated on a
prospective study with upfront DCE-CT and MRI.
Platelet count was more than 70,000 and liver enzymes
less than 6 times the upper limit of normal in all patients.
No patients had active hepatitis or decompensated
cirrhosis.
The AUC parameter of signal enhancement could not
discriminate any changes in tumor perfusion, perme-
ability, or dose-response effects and thus has little clinical
utility. Although it is recognized that there were a small
number of patients and tumors analyzed (n Z 6), the
lesions were found in all segments of the liver, with
variable dose and size, providing a wide scope for feasi-
bility testing.
The AIF functions in this study had relatively ﬂat
peaks which might be due to a slower injection protocol
(4 mL/second) and/or volume of contrast being injectedand less likely because of residual uncorrected respiration
motion given the extent of intrascan image registration. It
was shown in 1 case that the tumor histograms did not
signiﬁcantly change by using deformable image registra-
tion, and relative histogram changes over the course of
treatment are much more pronounced than differences
between double baseline and between motion correction
strategies. Nevertheless, it is recognized that image
registration between all phases of the DCE-CT scan could
further improve the results but for this to be practically
feasible 2 issues would have to be addressed. First, the
advent of even larger scan FOV such as the 640-slice
scanner could allow the entire liver to be present in all
phases of the DCE-CT time sequence. This would have to
be combined with improved liver autosegmentation
capabilities, likely on a graphics processing unit cluster,
to allow a deformable motion model to be created on the
entire time sequence, which contains around 60 volumes
in this case.
In summary, a volumetric perfusion CT methodology
has been presented and demonstrated feasibility in
obtaining 3D volumes of functional parameters such as
perfusion and permeability of both tumor and parenchyma
in patients with liver cancer. This is an important mile-
stone toward achieving a voxel-based, quantitative func-
tional imaging method that is sufﬁciently robust for use as
a prognostic imaging biomarker in this challenging dis-
ease, thus setting the stage for larger validation studies.Supplementary data
Supplementary material for this article (http://dx.doi.
org/10.1016/j.adro.2016.06.004) can be found at www.
practicalradonc.org.References
1. Rudin M. Imaging readouts as biomarkers or surrogate parameters
for the assessment of therapeutic interventions. Eur Radiol. 2007;17:
2441-2457.
2. Kim SH, Kamaya A, Willmann JK. CT perfusion of the liver:
principles and applications in oncology. Radiology. 2014;272:322-
344.
3. Jain RK. Normalization of tumor vasculature: An emerging concept
in antiangiogenic therapy. Science. 2005;307:58-62.
4. Coolens C, Driscoll B, Chung C, et al. Automated voxel-based
analysis of volumetric dynamic contrast-enhanced CT data
improves measurement of serial changes in tumor vascular bio-
markers. Int J Radiat Oncol Biol Phys. 2015;91:48-57.
5. Driscoll B, Keller H, Jaffray D, Coolens C. Development of a
dynamic quality assurance testing protocol for multisite clinical trial
DCE-CT accreditation. Med Phys. 2013;40:081906.
6. Goh V, Ng QS, Miles K. Computed tomography perfusion imaging
for therapeutic assessment: has it come of age as a biomarker in
oncology? Invest Radiol. 2012;47:2-4.
7. Miles KA, Grifﬁths MR. Perfusion CT: A worthwhile enhancement?
Br J Radiol. 2003;76:220-231.
Advances in Radiation Oncology: JulyeSeptember 2016 4D DCE-CT as a perfusion imaging biomarker for liver response 2038. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time
measurement of 3D tumor motion in lung due to breathing and
heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol
Phys. 2002;53:822-834.
9. Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the
liver. Semin Radiat Oncol. 2001;11:240-246.
10. Coolens C, Breen S, Purdie TG, et al. Implementation and charac-
terization of a 320-slice volumetric CT scanner for simulation in
radiation oncology. Med Phys. 2009;36:5120-5127.
11. Brade AM, Kim J, Brierley J, et al. Phase I study of sorafenib and
whole liver radiotherapy (WLRT) or stereotactic body radiotherapy
(SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2012;84:
S11-S12.
12. Coolens C, Bracken J, Driscoll B, Hope A, Jaffray D. Dynamic
volume vs respiratory correlated 4DCT for motion assessment in
radiation therapy simulation. Med Phys. 2012;39:2669-2681.
13. Miles KA. Perfusion CT for the assessment of tumour vascularity:
Which protocol? Br J Radiol. 2003;76:S36-S42.
14. Nguyen TN, Moseley JL, Dawson LA, Jaffray DA, Brock KK.
Adapting liver motion models using a navigator channel technique.
Med Phys. 2009;36:1061-1073.
15. Coolens C, Driscoll B, Chung C, et al. Automated voxel-based
analysis of volumetric DCE-CT data improves the measurement of
serial changes in tumor vascular biomarkers. Int J Radiat Oncol Biol
Phys. 2015;91:48-57.
16. Driscoll B, Keller H, Coolens C. Development of a dynamic ﬂow
imaging phantom for dynamic contrast-enhanced CT. Med Phys.
2011;38:4866-4880.
17. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters
from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable
tracer: Standardized quantities and symbols. J Magn Reson Imaging.
1999;10:223-232.18. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS. Perfusion
imaging of the liver: Current challenges and future goals. Radiology.
2005;234:661-673.
19. Eccles C, Brock KK, Bissonnette JP, Hawkins M, Dawson LA.
Reproducibility of liver position using active breathing coordinator
for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:
751-759.
20. Hompland T, Ellingsen C, Galappathi K, Rofstad EK. DW-MRI in
assessment of the hypoxic fraction, interstitial ﬂuid pressure, and met-
astatic propensity of melanoma xenografts. BMC Cancer. 2014;14:92.
21. Cyran CC, Paprottka PM, Schwarz B, et al. Perfusion MRI for
monitoring the effect of sorafenib on experimental prostate carci-
noma: A validation study. AJR Am J Roentgenol. 2012;198:384-391.
22. Li Y, Li S, Zhu Y, et al. Incidence and risk of sorafenib-induced
hypertension: A systematic review and meta-analysis. J Clin
Hypertension (Greenwich, Conn). 2014;16:177-185.
23. Kettunen MI, Brindle KM. Apoptosis detection using magnetic
resonance imaging and spectroscopy. Progr Nucl Magnet Res
Spectrosc. 2005;47:175-185.
24. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria
in Solid Tumors) criteria: Implications for diagnostic radiologists. Br
J Radiol. 2001;74:983-986.
25. Ng CS, Chandler AG, Wei W, et al. Effect of dual vascular input
functions on CT perfusion parameter values and reproducibility in
liver tumors and normal liver. J Comput Assist Tomogr. 2012;36:
388-393.
26. Wang H, Farjam R, Feng M, et al. Arterial perfusion imaging-
deﬁned subvolume of intrahepatic cancer. Int J Radiat Oncol Biol
Phys. 2014;89:167-174.
27. Cao Y, Pan C, Balter JM, et al. Liver function after irradiation based
on computed tomographic portal vein perfusion imaging. Int
J Radiat Oncol Biol Phys. 2008;70:154-160.
